Search Results

Your search for Syed Ali Abutalib, MD, and Julie M. Vose, MD, MBA, FASCO,Syed Ali Abutalib, MD, and Julie M. Vose, MD, MBA, FASCO matches 2 pages

Showing 1 - 2

By Syed Ali Abutalib, MD, and Julie M. Vose, MD, MBA, FASCO / March 25, 2021

Challenges in Managing Hodgkin Lymphoma: Focus on Use of Brentuximab Vedotin

“I was taught that the way of progress was neither swift nor easy.” —Marie Curie To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two abstracts selected from the meeting proceedings focusing on...

lymphoma

immunotherapy

By Syed Ali Abutalib, MD, and Julie M. Vose, MD, MBA, FASCO / February 25, 2021 / 2020 ASH Annual Meeting & Exposition

B-Cell and T-Cell Non-Hodgkin Lymphomas

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the assessment and treatment of patients with B-cell and T-cell non-Hodgkin...

Nov

Today In Oncology

Search Results

Your search for Syed Ali Abutalib, MD, and Julie M. Vose, MD, MBA, FASCO,Syed Ali Abutalib, MD, and Julie M. Vose, MD, MBA, FASCO matches 2 pages

Challenges in Managing Hodgkin Lymphoma: Focus on Use of Brentuximab Vedotin

B-Cell and T-Cell Non-Hodgkin Lymphomas

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC